Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-928-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Chiasma (NASDAQ:CHMA) Frequently Asked Questions
What is Chiasma's stock symbol?
Chiasma trades on the NASDAQ under the ticker symbol "CHMA."
How were Chiasma's earnings last quarter?
Chiasma Inc (NASDAQ:CHMA) released its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.04. View Chiasma's Earnings History.
When is Chiasma's next earnings date?
What price target have analysts set for CHMA?
5 equities research analysts have issued 12-month price targets for Chiasma's stock. Their predictions range from $11.00 to $18.00. On average, they anticipate Chiasma's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 192.3% from the stock's current price. View Analyst Price Targets for Chiasma.
What is the consensus analysts' recommendation for Chiasma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.
Has Chiasma been receiving favorable news coverage?
News coverage about CHMA stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chiasma earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Chiasma.
Are investors shorting Chiasma?
Chiasma saw a increase in short interest in September. As of September 30th, there was short interest totalling 2,210,000 shares, an increase of 53.5% from the August 30th total of 1,440,000 shares. Based on an average daily volume of 799,800 shares, the days-to-cover ratio is currently 2.8 days. Currently, 7.4% of the shares of the stock are sold short. View Chiasma's Current Options Chain.
Who are some of Chiasma's key competitors?
Some companies that are related to Chiasma include CannTrust (CNTTF), Emisphere Technologies (EMIS), ZEALAND PHARMA/S (ZEAL), Cara Therapeutics (CARA), Omeros (OMER), Rhythm Pharmaceuticals (RYTM), ZIOPHARM Oncology (ZIOP), Stoke Therapeutics (STOK), Organogenesis (ORGO), Vectura Group (VEGPF), Principia Biopharma (PRNB), Vanda Pharmaceuticals (VNDA), Wave Life Sciences (WVE), Cytokinetics (CYTK) and Homology Medicines (FIXX).
What other stocks do shareholders of Chiasma own?
Who are Chiasma's key executives?
Chiasma's management team includes the folowing people:
- Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)
- Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
- Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54)
- Dr. Gary Patou, Head of Clinical (Age 60)
When did Chiasma IPO?
(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.
How do I buy shares of Chiasma?
Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chiasma's stock price today?
One share of CHMA stock can currently be purchased for approximately $4.79.
How big of a company is Chiasma?
Chiasma has a market capitalization of $200.99 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.
What is Chiasma's official website?
How can I contact Chiasma?
Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]
MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
